Enter Johnson! Using Ebola platform to develop new coronavirus vaccine and construct antiviral molecular library

Johnson is the first novel coronavirus vaccine to be announced and has successfully developed and produced a vaccine against Ebola virus Now, it is expanding cooperation with many institutions to accelerate the development of new coronavirus (covid-19) vaccine The novel coronavirus vaccine has been developed by Johnson in collaboration with the BARDA Johnson & Johnson is trying to raise funds and resources with BARDA to speed up the process of drug development in the first phase Currently, Johnson & Johnson has joined a number of biopharmaceutical companies that are trying to curb the spread of the coronavirus Johnson & Johnson has initially developed a multi pronged approach to the virus, which enables it to provide antiviral drugs in China, and at the same time, using Yang Sen's AdVac? Adenovirus vector platform and / or PER.C6? Production cell line technology, quickly developed a vaccine that can protect people from COVID-19 infection According to a statement released by Johnson & Johnson at the end of last month, the company's response plan also includes checking known pathways in the pathogenesis of coronavirus to determine whether previously tested drugs can be used to help patients resist coronavirus infection and reduce the severity of non fatal cases According to the global head of its virus vaccine research and development center, the new vaccine will stimulate the human immune response through injection, and it is expected to take at least eight months to put into mass production Johnson & Johnson is expanding its alliance with BARDA, a division of the U.S Department of health and human services Janssen Pharmaceutical, a subsidiary of the company, and BARDA will jointly fund the research and development of the vaccine and provide funds and resources for the project In addition to the vaccine program, the program will explore an antiviral molecular library to quickly track the identification of potential new coronavirus therapies The two sides will invest money to shorten the time it takes for the vaccine to reach the first phase Once the vaccine enters the clinic, more funds may be available to support the development of the vaccine At that stage, J & J may also seek support from other partners to expand vaccine access "We are still in discussions with other partners and if we have a potential vaccine candidate, our goal is to make it available to China and the rest of the world," Paul Stoffels, chief scientific officer of Johnson & Johnson, said in a statement Although BARDA's involvement may accelerate the program, the basic scope of the project remains the same The focus is still on using Johnson & Johnson's per.c6 production system and advac adenovirus vector development and production system to quickly develop a vaccine that can protect people from new coronavirus infection J & J recently started a similar vaccine development program The Ebola vaccine, developed with advac and per.c6, is being tested in Africa, and Johnson & Johnson has applied the technology to prophylactics against Zika, HIV and RSV.